SAM
BMRN icon

Shamrock Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Shamrock Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-100
Closed -$9K – 257
2016
Q3 		$9K Buy
+100
New +$9.42K 0.01% 228

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Shamrock Asset Management's BMRN Position: Q4 2016 in Review

Shamrock Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2016, closing a stake of 100 shares — an estimated $9K sold.

Shamrock Asset Management first reported a position in BMRN in Q3 2016 and held it in 1 quarter. The position peaked at $9K in Q3 2016. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • Shamrock Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Shamrock Asset Management sold 100 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $9K.
  • Shamrock Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Shamrock Asset Management's BioMarin Pharmaceuticals position peaked at $9K in Q3 2016.
  • 415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Shamrock Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.